Corneal Rejuvenation with Trefoil Therapeutics

<p class="MsoNormal">In this episode, I discuss corneal disease and treatments with <strong>David Eveleth, PhD,</strong> the founder, president and CEO of Trefoil Therapeutics.</p> <p class="MsoNormal"><em>Brought to you by Alcon</em></p> <p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';">      </span></span></span> <!--[endif]-->Welcome to another exciting episode of Eye Care insider <strong><em>:14</em></strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';">      </span></span></span> <!--[endif]-->Intro David Eveleth, PhD <strong><em>:47</em></strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';">      </span></span></span> <!--[endif]-->Eveleth’s background <strong><em>1:05</em></strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';">      </span></span></span> <!--[endif]-->What’s the treatment landscape now for corneal diseas